Oppenheimer raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $7 and keeps an Outperform rating on the shares following quarterly results. The firm cites outlook for continued commercial execution and sustainable growth.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: